Kaohsiung Medical University

Metal Industries Research & Development Centre

National Dong Hwa University

Realinn Life Science Limited

Ying-Chi Du

Yang-Chang Wu

Fang-Rong Chang

Mei-Chin Lu

Tung-Ying Wu

Tusty-Jiuan Hsieh

Yi-Hong Tsai

Yu-Ming Hsu

Chun-Chieh Lin

Suh-Hang Hank Juo

An-Shen Lin

Tzu-Chen Kuo

Jui-Chi Tsai

Yu-Ming Fan

Pei-Jung Lien

Chuan-Chia Sun

Jen Cheng Lin

Sheng-Chung Yang

Ming-Kai Weng

Fu-Wen Kuo

Chi-Ting Hsieh

Ping-Jyun Sung

Hsu-Tung Lee

Jui-Hsin Su

Kuei-Hung Lai

Yi-Chang Liu

The present invention relates to a novel type of PPARγ modulator having a pyrimido[5,4-d]pyrimidine main structure. The PPARγ modulator can enhance the expression and nuclear translocation of PPARγ in cells. The present invention also relates to a pharmaceutical composition comprising the PPARγ modulator of the invention encapsulated in a pharmaceutically acceptable cell-penetrating drug delivery system so that it can be directly delivered into cells. The present invention thus provides a method of preventing or treating PPARγ-related disorders or conditions comprising administering to a subject in need thereof a therapeutically effective amount of the PPARγ modulator of the invention or the pharmaceutical composition of the invention.

Compounds for enhancing PPARγ expression and nuclear translocation and therapeutic use thereof

Theextract of the present invention is prepared using supercritical fluid technique, wherein the method includes steps of: (a) drying the leaves of; (b) pulverizing the leaves as particles; and (c) extracting the particles with supercritical carbon dioxide to obtain theextract. This supercriticalextract not only can decrease blood sugar level, but also promotes lipid degradation, inhibits the formation of huge lipid droplet and improves the metabolic symptoms. Accordingly, theextract further is able to be prepared as food supplement and pharmaceuticals.

Extract offrom supercritical fluid extraction for treating diabetes and metabolic disease, the preparation method and the use thereof

The present invention discloses scalarane sesterterpenoids represented by formula (I) and meroditerpenoid represented by formula (II), which are extracted fromsp. sponge: where Ris &#x2014;CHor &#x2014;CH. The compounds of formula (I) can be used to be an anticancer, act as an inhibitor targeting to topoisomerase II and hsp90 and a pharmaceutical composition for anticancer.

Scalarane sesterterpenoid, pharmaceutical composition and topoisomerase II and Hsp90 inhibitor for treating cancer, and use and preparation method thereof

Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4'-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPAR&#x3b3; inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPAR&#x3b3; ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1&#x3b2; (IL-1&#x3b2;) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL).

Composition for treating atherosclerosis and a preparation method thereof

A preparation method for a water extract of the fruiting body of(ACW) is provided. The method includes steps of: (a) providing the fruiting body; and (b) boiling the fruiting body in water to obtain the water extract. This polysaccharide-rich water extract frominduces the maturation of dendritic cells, enhances T cell proliferation and INF-&#x3b3; production, and polarizes them toward the Th1 pathway. ACW can be effectively applied in cancer immunotherapy.

[object Object]

Disclosed is a chalcone composition for treating diabetes and metabolic syndromes. In particular, the chalcone compound bound with 2-halogen in ring A significantly decreases the blood glucose level in the in vitro anti-diabetic effect experiment. In the in vivo animal model, the leading chalcone compound can prevent the progression of diabetes and control the blood glucose level, and there is no significant difference in the gains in body weight. Throughout the seven-week administration, there are no hepatic or renal toxicity observed.

Composition for treating diabetes and metabolic diseases and a preparation method thereof

A preparation method for an ethanol extract of the fruiting body of(EEAC) is provided. The preparation method includes steps of: (a) providing the fruiting body of(AC); (b) extracting the fruiting bodies with a first ethanol solution; and (c) obtaining EEAC. EEAC further can be sequentially extracted or fractioned by n-hexane, ethyl acetate and ethanol, and an n-hexane fraction (FC), an ethyl acetate fraction (FA) and an ethanol fraction (FB) respectively are generated. The growth inhibition and apoptosis induction of leukemia cell line HL 60 are effectively mediated by FA product, in which zhankuic acid A is the bioactive marker. The amount of triterpenoid in the fruiting body of AC can be determined by NMR and HPLC analysis.

Disclosed are a method for preparing an n-hexane extract of the fruiting body of(AC), wherein the fruiting body of AC is sequentially extracted with the ethanol solution and the n-hexane solution to obtain the n-hexane extract containing at least one benzenoid compound. The amounts of 4,7-dimethoxy-5-(3-methylbut-3-en-1-ynyl)-6-methyl-1,3-benzodioxole, 4,7-dimethoxy-5-methyl-1,3-benzodioxole, antrocamphine A and the combination thereof in the at least one benzenoid compound are determined using chromatography, NMR and HPLC. In addition, the present invention is applicable on detecting the amounts of benzenoid compounds in the AC healthcare food/drug or the fruiting body of AC, and thus owns the industrial values.

Benzenoid compounds of antrodia cinnamomea, preparation and analysis method thereof

Growing community of inventors

Chiayi, Taiwan

Ying-Chi Du